
DEVELOPMENT OF BIOACTIVE MOLECULES FOR THE TREATMENT OF ALZHEIMER'S DISEASE


Amisha Punmiya¹, Ruchita Gharat¹, Dr. Arati Prabhu¹ ¹SVKM's Dr. Bhanuben Nanavati College Of Pharmacy, Mumbai, India

Alzheimer's disease \rightarrow progressive brain disease \rightarrow wreaks havoc on memory and thinking skills, capacity to carry INTRODUCTION out even the most basic tasks. AD \rightarrow the most common dementia subtype, accounting for nearly 70% of all dementias. Current drugs \rightarrow Provide symptomatic treatment. These therapies show only a little, but consistent, improvement in cognitive and functional ability. Prolonged use \rightarrow Cause side effects. The understanding of the multifactorial hypothesis of Alzheimer's disease and the possibility of utilizing a multi-target approach provides promise for the development of new and effective treatments for the disease.


RATIONALE


Develop a series of thiophene-pyrazoline compounds with potential to address the various causative biochemical events that cause Alzheimer's disease.











FTIR


Cm⁻¹

Smoothing


TLC


SOLUBILITY

COMPARISON OF ACTIVITIES FOR TESTED MOLECULES














REFERENCES

1. Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and Emerging Drug Treatment Options for Alzheimer's Disease. Drugs. 2. Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JCL. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry. 2018;26(4). 3. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020

report of the Lancet Commission. Vol. 396, The Lancet. 2020.



While the antioxidant activities of the synthesized thiophene pyrazoline molecules needs further optimization, the series as such showed excellent potential in mitigating the multiple causative factors implicated in Alzheimer's disease viz $A\beta$ aggregation inhibition, AChE inhibition, metal chelation and inhibition of advanced glycation end-products.

ECMC 2022

The 8th International Electronic **Conference on Medicinal Chemistry** 01-30 NOVEMBER 2022 ONLINE